Tourmaline Bio to Host Expert Webinar on Human Genetic Validation for IL-6 Inhibition in Cardiovascular Disease with Dr. Dipender Gill on Friday, November 1, 2024
October 15, 2024 07:30 ET
|
Tourmaline Bio, Inc.
Tourmaline Bio to Host Expert Webinar on Human Genetic Validation for IL-6 Inhibition in Cardiovascular Disease with Dr. Dipender Gill on Friday, November
Tourmaline Bio to Showcase Two Poster Presentations at the 2024 Cardiometabolic Health Congress
October 11, 2024 07:30 ET
|
Tourmaline Bio, Inc.
Tourmaline Bio to Showcase Two Poster Presentations at the 2024 Cardiometabolic Health Congress
Tourmaline Bio Announces Formation of Cardiovascular Scientific Advisory Board
October 08, 2024 07:30 ET
|
Tourmaline Bio, Inc.
Tourmaline Bio Announces Formation of Cardiovascular Scientific Advisory Board
Tourmaline Bio to Present at Upcoming Investor Conferences
September 03, 2024 07:45 ET
|
Tourmaline Bio, Inc.
Tourmaline Bio to Present at Upcoming Investor Conferences
Tourmaline Bio Reports Second Quarter 2024 Financial Results and Recent Business Highlights
August 08, 2024 07:30 ET
|
Tourmaline Bio, Inc.
Tourmaline Bio Reports Second Quarter 2024 Financial Results and Recent Business Highlights
Tourmaline Bio Presents Phase 2 TRANQUILITY Study Design at American Society of Preventive Cardiology (ASPC) Congress 2024
August 02, 2024 16:30 ET
|
Tourmaline Bio, Inc.
Tourmaline Bio Presents Phase 2 TRANQUILITY Study Design at American Society of Preventive Cardiology (ASPC) Congress 2024
Tourmaline Bio Announces the Promotion of Ryan Robinson to Chief Financial Officer
June 27, 2024 08:05 ET
|
Tourmaline Bio, Inc.
Tourmaline Bio Announces the Promotion of Ryan Robinson to Chief Financial Officer
Tourmaline Bio to Present at the Jefferies Global Healthcare Conference
May 23, 2024 07:10 ET
|
Tourmaline Bio, Inc.
Sandeep Kulkarni, CEO of Tourmaline Bio, is expected to participate in the Jefferies Global Healthcare Conference in New York on June 9, 2024
Tourmaline Bio Initiates Clinical Development of TOUR006 for Cardiovascular Diseases with First Patient Dosed in Phase 2 TRANQUILITY Trial
May 16, 2024 07:00 ET
|
Tourmaline Bio, Inc.
Tourmaline Bio Initiates Clinical Development of TOUR006 for Cardiovascular Diseases with First Patient Dosed in Phase 2 TRANQUILITY Trial
Tourmaline Bio Reports First Quarter 2024 Financial Results and Recent Business Highlights
May 13, 2024 07:00 ET
|
Tourmaline Bio, Inc.
Tourmaline Bio announces financial results and business highlights for the first quarter ended March 31, 2024